Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1988 1
1991 1
1992 1
1993 1
1994 2
1995 1
1996 1
1997 4
1998 5
1999 6
2000 4
2001 8
2002 10
2003 3
2004 13
2005 13
2006 14
2007 20
2008 20
2009 28
2010 26
2011 34
2012 31
2013 40
2014 41
2015 33
2016 50
2017 38
2018 34
2019 34
2020 23
2021 21
2022 17
2023 16
2024 16
2025 14
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Results by year

Filters applied: . Clear all
Page 1
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.
Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. Oh SC, et al. Among authors: noh sh. Nat Commun. 2018 May 3;9(1):1777. doi: 10.1038/s41467-018-04179-8. Nat Commun. 2018. PMID: 29725014 Free PMC article.
PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. Kang YK, et al. Among authors: noh sh. J Clin Oncol. 2021 Sep 10;39(26):2903-2913. doi: 10.1200/JCO.20.02914. Epub 2021 Jun 16. J Clin Oncol. 2021. PMID: 34133211 Free PMC article. Clinical Trial.
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Bang YJ, et al. Among authors: noh sh. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7. Lancet. 2012. PMID: 22226517 Clinical Trial.
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Morano F, Wotherspoon A, Valeri N, Kook MC, An JY, Grabsch HI, Fucà G, Noh SH, Sohn TS, Kim S, Di Bartolomeo M, Cunningham D, Lee J, Cheong JH, Smyth EC. Pietrantonio F, et al. Among authors: noh sh. J Clin Oncol. 2019 Dec 10;37(35):3392-3400. doi: 10.1200/JCO.19.01124. Epub 2019 Sep 12. J Clin Oncol. 2019. PMID: 31513484 Free article.
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Noh SH, et al. Lancet Oncol. 2014 Nov;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439693 Clinical Trial.
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Cheong JH, Jeong O, Heo MH, Kim HK, Park C, Yoo CH, Kang SY, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Hwang JE, Ryu SW, Kook MC, Ryoo BY, Kim H, Yoo MW, Lee NS, Lee SH, Noh SH. Kang YK, et al. Among authors: noh sh. J Clin Oncol. 2024 Sep 1;42(25):2961-2965. doi: 10.1200/JCO.23.02167. Epub 2024 Jul 12. J Clin Oncol. 2024. PMID: 38996201 Clinical Trial.
Clinical application of whole-genome sequencing of solid tumors for precision oncology.
Kim R, Kim S, Oh BB, Yu WS, Kim CW, Hur H, Son SY, Yang MJ, Cho DS, Ha T, Heo S, Jang JY, Yun JS, Kwack KS, Kim JK, Huh J, Lim SG, Han SU, Lee HW, Park JE, Kim CH, Roh J, Koh YW, Lee D, Kim JH, Lee GH, Noh CK, Jung YJ, Park JW, Sheen S, Ahn MS, Choi YW, Kim TH, Kang SY, Choi JH, Baek SY, Lee KM, Il Kim S, Noh SH, Kim SH, Hwang H, Joo E, Lee S, Shin JY, Yun JY, Park J, Yi K, Kwon Y, Lee WC, Park H, Lim J, Yi B, Koo J, Koh JY, Lee S, Lee Y, Lee BR, Connolly-Strong E, Ju YS, Kwon M. Kim R, et al. Among authors: noh sh. Exp Mol Med. 2024 Aug;56(8):1856-1868. doi: 10.1038/s12276-024-01288-x. Epub 2024 Aug 13. Exp Mol Med. 2024. PMID: 39138315 Free PMC article.
Colloidal Synthesis of P-Type Zn3As2 Nanocrystals.
Kim S, Lee K, Gwak N, Shin S, Seo J, Noh SH, Kim D, Lee Y, Kong H, Yeo D, Kim TA, Lee SY, Jang J, Oh N. Kim S, et al. Among authors: noh sh. Adv Mater. 2024 May;36(21):e2310671. doi: 10.1002/adma.202310671. Epub 2024 Feb 6. Adv Mater. 2024. PMID: 38279779
541 results